Proceedings of the National Academy of Sciences, Volume 123, Issue 35, September 2026. <br/>SignificanceEpstein–Barr virus (EBV) causes approximately 200,000 cancer deaths annually, yet therapeutic options remain limited by broad immunosuppression and variable efficacy. We demonstrate that SIRT2 deacylase modulators block EBV-driven B cell …
Source link
Headlines
